Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Leases (2019 - 2025)

Bicycle Therapeutics' Operating Leases history spans 7 years, with the latest figure at $14.1 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 253.28% year-over-year to $14.1 million; the TTM value through Dec 2025 reached $14.1 million, up 253.28%, while the annual FY2025 figure was $14.1 million, 253.28% up from the prior year.
  • Operating Leases reached $14.1 million in Q4 2025 per BCYC's latest filing, up from $981000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $14.4 million in Q1 2023 to a low of $981000.0 in Q3 2025.
  • Average Operating Leases over 5 years is $7.9 million, with a median of $8.7 million recorded in 2023.
  • Peak YoY movement for Operating Leases: soared 2735.92% in 2021, then plummeted 82.27% in 2025.
  • A 5-year view of Operating Leases shows it stood at $12.1 million in 2021, then decreased by 9.9% to $10.9 million in 2022, then fell by 13.81% to $9.4 million in 2023, then plummeted by 57.47% to $4.0 million in 2024, then skyrocketed by 253.28% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Operating Leases are $14.1 million (Q4 2025), $981000.0 (Q3 2025), and $1.8 million (Q2 2025).